Piramal Enterprises Ltd.
Snapshot View

2507.65 +18.30 ▲0.7%

03 August 2021, 04:00:00 P.M.
Volume: 74,547

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.piramal.com
Financial Indicators
Market Cap 56,942.27 Cr.
Earnings per share (EPS) 58.67 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 42.74 Trailing Twelve Months Ending 2021-03
Industry PE 32.95 Trailing Twelve Months Ending 2021-03
Book Value / Share 1,506.89 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.66 Calculated using Price: 2,507.65
Dividend Yield 1.32 Period Ending 2021-03
No. of Shares Subscribed 22.71 Cr. 227,074,234 Shares
FaceValue 2
Company Profile

Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.

PEL made its foray into the financial services sector with Piramal Capital & Housing Finance Limited (PCHFL), a housing finance company registered with the National Housing Bank (NHB) that is engaged in various financial services businesses. It provides end-to-end financing solutions in both wholesale and retail funding opportunities across sectors such as real estate and infrastructure, renewable energy, hospitality, logistics, industrials, auto components etc. Through its group companies, the platform has strategic partnerships with leading global pension funds such as Canadian Pension Plan Investment Board (CPPIB), APG and Ivanhoe Cambridge.

Products and services offered by the company

Piramal Pharma

  • Pharma Solutions
  • Critical Care
  • Consumer Products
  • PhytoMedicine

Financial Services

  • Piramal Capital & Housing Finance
  • India Resurgence Fund (IndiaRF)

Awards & Recognitions

For Financial Services

  • Piramal Capital & Housing Finance Limited was awarded Best Overall Investment Manager for Real Estate in India at the 15th Annual Euromoney Real Estate Survey 2019 - September 2019.
  • Piramal Capital & Housing Finance Limited won ?Best Private Equity Deal of the Year at the 11th Estate Awards by Franchise India - August 2019.
  • Piramal Capital & Housing Finance Limited was awarded ?Best In-House Legal Team of the Year in the Banking and Financial Services sector at the Asian Legal Business India Law Awards 2020 - March 2020.

For Pharma

  • Piramal Pharma Solutions was honoured with the ?Frost & Sullivan Global Customer Service Leadership Award - June 2019.
  • Piramal Pharma Solutions was ranked 1st by Biospectrum India in Bio Services - October 2019.
  • Piramal Pharma Solutions won the ?2020 Manufacturing Supply Chain Operational Industry Excellence Award within the Pharmaceuticals Category at the 9th Edition of Manufacturing Supply Chain Awards - March 2020. 

Milestones

  • 1980: In the early 1980s a young Ajay Piramal takes the reins of the Piramal Group.
  • 1984: Acquired Gujarat Glass
  • 1988: Acquired Nicholas Laboratories.
  • 1990: Gujarat Glass is merged with the group company, Nicholas Piramal India Ltd
  • 1991: A new formulation plant at Pithampur in Madhya Pradesh is commissioned.
  • 1992: Set up a second formulation plant at Pithampur in Madhya Pradesh with state-of-the-art manufacturing facilities.
  • 1992: Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.
  • 1993: Piramal entered into a joint venture agreement with Allergan of U.S.A., the leading manufacturers of Ophthalmic products.
  • 1994: A joint venture agreement was entered into with Satelec, France for dental care products.
  • 1995: The bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad transferred to NPIL.
  • 1996: Entered into a product tie-up with F. Hoffman-La-Roche.
  • 1996: Boehringer Mannheim is acquired.
  • 1997: NPIL entered into an agreement with Reckitt & Colman for joint marketing of the latter's OTC products in India.
  • 1998: Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.
  • 1998: Nicholas Piramal India Ltd (NPIL) forges joint venture with Boots Healthcare International (BHI) to develop and market consumer healthcare products in India.
  • 2000: Rhone Poulenc India Limited is acquired.
  • 2000: Started collaborative research with Centre for Biochemical Technology in the field of gene technology.
  • 2000: Research alliance established with Hindustan Lever for developing Cosmoceuticals and personal care products.
  • 2002: ICI Pharma is acquired.
  • 2003: Global Bulk Drugs is acquired.
  • 2004: Nicholas forges alliance with scientists from Imperial College of the UK to carry out research in the field of rheumatoid arthritis.
  • 2005: Avecia Pharmaceutical is acquired.
  • 2006: Pfizer's Morpeth UK facility acquired.
  • 2007: Scientists from Piramal led the first exploration by an Indian pharmaceutical company to develop drug leads from geographies like Antarctica.
  • 2008: Khandelwal Laboratories is acquired.
  • 2009: RxEliteinc, the U.S. based inhalation anesthetic gas distribution business, is acquired.
  • 2010: Biosyntech, Inc., Canada is acquired by Piramal Enterprises Ltd., part of the Life Sciences vertical, Bio-Orthopedics division.
  • 2010: Piramal sells the diagnostics division to Super Religare Laboratories Ltd.
  • 2010: Acquisition of iPill, an oral contraceptive brand, from Cipla.
  • 2011: Bharat Serum and Vaccines Ltd - Anaesthetics business buyout by Piramal Enterprises Ltd.
  • 2011: Piramal Realty acquires Mafatlal Mills in Byculla, Mumbai.
  • 2011: Piramal Healthcare acquires 11% of Vodafone India.
  • 2011: UN Conference on Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide.
  • 2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
  • 2011: Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India.
  • 2011: Piramal's Pharma Solutions manufacturing site at Grangemouth, Scotland becomes the world’s first contract supplier at commercial scale for ADCs.
  • 2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
  • 2012: Piramal Realty wins the auction of the landmark Hindustan Unilever training centre at Worli Sea Face, Mumbai.
  • 2012: Decision Resources Group acquires Abacus International, a UK based global market access solutions company for many of the world’s leading health care companies.
  • 2012: BST-CarGel, company’s innovative bio-orthopedic product for cartilage repair, receives European CE mark approval.
  • 2012: Piramal Enterprises starts a Non-Banking Financial Company (NBFC) focused on lending to real estate, education and hospitals
  • 2012: Piramal Enterprises acquires health care information management firm, Decision Resources Group, USA for US$635 million
  • 2012: Piramal Realty, a privately owned real estate entity, was formed
  • 2012: Piramal Healthcare Limited is renamed to Piramal Enterprises Limited.
  • 2013: Piramal Enterprises Limited acquires Molecular Imaging Development portfolio of Bayer Pharma
  • 2013: Imaging division's lead radiopharmaceutical, Florbetaben, accepted for review by the US FDA and EMA for the visual detection of Beta-Amyloid in Alzheimer's disease
  • 2013: Piramal Water (Sarvajal) honoured with 'Enabling Technology Award of the Year 2013' by Frost & Sullivan
  • 2013: Piramal Enterprises Ltd. consumer products' division acquires the brand CALADRYL® in India.
  • 2014: APG Asset Management, the Dutch pension fund asset manager and Piramal Enterprises Limited announce a strategic alliance for investing in rupee denominated mezzanine instruments issued by infrastructure companies in India with a target investment of US$1 billion, over the next 3 years
  • 2014: Piramal Enterprises Limited acquires 9.99% equity stake in Shriram City Union Finance Limited
  • 2014: Piramal Enterprises Limited agrees to acquire an effective 20% equity stake in Shriram Capital Limited, a financial services company, for an aggregate consideration of INR 20.14 Billion
  • 2014: Canada Pension Plan Investment Board (CPPIB) and Piramal Enterprises Limited announce a US$500 million Strategic Alliance for Residential Development Debt Financing in India; appoint Piramal Fund Management (at the time known as Indiareit) as advisor
  • 2015: Piramal Enterprises Ltd. acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.
  • 2015: DRG has acquired Healthcare Business Insights (HBI), a trusted provider of best Practice research, training and services to more than 1,400 hospitals across the U.S.
  • 2015: Warburg Pincus to invest Rs 1800 crore in Piramal Realty.
  • 2015: Piramal Realty secures $150 million (Rs 900 crore) from Goldman Sachs.
  • 2015: Piramal Realty launches a new community for natural and holistic living at Balkum, Thane, Mumbai: Piramal Vaikunth
  • 2015: Piramal Enterprises acquires the Baby Care brand – Little’s for the Consumer Products Business
  • 2016: Piramal Enterprises announces the sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew
  • 2016: Piramal Realty launches its signature project, Piramal Aranya in Byculla, Mumbai
  • 2016: Piramal Enterprises enters an agreement to acquire four brands from Pfizer Limited for its Consumer Products Business
  • 2016: Piramal Realty forays into commercial real estate with the launch of Piramal Agastya Corporate Park in Kurla, Mumbai
  • 2016: Piramal Enterprises enters into an agreement to acquire Ash Stevens Inc., a US based Contract and Drug Manufacturing Organisation (CDMO) for High Potency APIs (HPAPIs)
  • 2016: Piramal Enterprises Limited and Bain Capital Credit to pursue distressed debt investing in India
  • 2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
  • 2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
  • 2016: Piramal Fund Management launches an Innovative Flexi Lease Rental Discounting (LRD) for Commercial Assets.
  • 2017: Piramal Enterprises Limited announces its plan to enter Housing Finance
  • 2017: Piramal Enterprises Limited and Ivanhoé Cambridge announce Partnership to Invest in Residential Developments in India
  • 2017: Piramal Realty marks exclusive pre-Launch of Piramal Revanta
  • 2017: Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC.
  • 2018: Piramal Finance Limited Forays into the Hospitality Sector
  • 2018: Piramal Realty launches Piramal Mahalaxmi, its Flagship Project in South Mumbai
  • 2018: NITI Aayog Partners with Piramal Foundation to Transform 25 Aspirational Districts across 7 states in India, in the areas of Health & Nutrition and Education.
  • 2018: IndiaRF Announces $156 million Investment in Archean Group’s Marine Chemicals Business.
  • 2019: Piramal Enterprises Limited signed a Memorandum of Understanding with Canada Pension Plan Investment Board (CPPIB) to set-up Asset Aggregation Platform focused on renewables.
  • 2019: Supreme Court Exempts Saridon from the List of Banned FDCs.
  • 2019: Piramal Swasthya has been recognized by USAID with the ‘Inclusive Health Access Award’ for its High Impact Healthcare Platform
  • 2019: Piramal Foundation and Gates Foundation Partner to Setup a Tribal Health Collaborative for India
  • 2019: Piramal Swasthya and The Rockefeller Foundation Announce Partnership to Accelerate India’s Public Health Transformation
  • 2019: Piramal Divests its DRG Business for $950 million.
  • 2019: PEL raises funds of Rs 14,500 crore in FY2020.
  • 2019: Piramal Realty Makes a Foray into Value Housing Segment
  • 2020: Piramal Group Commits INR 25 Crores to COVID-19 Relief Effort.
  • 2020: Carlyle and Piramal Pharma Sign Agreement on 20% Strategic Growth Investment.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.74%
1 Week
+8.75%
1 Month
+4.23%
3 Month
+46.93%
6 Month
+65.59%
1 Year
+71.74%
2 Year
+47.03%
5 Year
+62.95%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -1.98 -4.96 25.55 5.76 7.78 23.36 4.26 -1.62 3.33
Return on Capital Employed (%) 2.41 3.30 18.70 7.19 8.96 8.52 7.93 8.81 10.03
Return on Assets (%) -1.02 -2.01 10.59 2.35 2.46 7.62 1.41 -0.56 1.33

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 10,724 9,321 11,736 12,948 14,883 26,562 27,224 30,572 34,018
Non Curr. Liab. 1,598 6,710 7,817 11,760 18,776 25,355 29,033 24,454 34,163
Curr. Liab. 11,765 9,490 5,694 10,542 18,962 22,479 31,213 23,673 13,347
Minority Int. 12 29 0 13 12 9 1,121
Equity & Liab. 24,099 25,521 25,276 35,250 52,634 74,409 87,480 78,699 82,649
Non Curr. Assets 16,398 21,149 19,912 30,595 43,471 61,843 75,089 62,586 62,782
Curr. Assets 7,701 4,372 5,364 4,655 9,163 12,566 12,390 16,113 19,867
Misc. Exp. not W/O
Total Assets 24,099 25,521 25,276 35,250 52,634 74,409 87,480 78,699 82,649

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 3,520 4,503 5,123 6,342 8,504 10,631 13,215 14,423 12,809
Other Income 196 225 255 252 234 264 317 521 364
Total Income 3,716 4,728 5,377 6,593 8,737 10,895 13,532 14,944 13,173
Total Expenditure -3,105 -3,868 -4,238 -4,649 -5,005 -5,476 -6,573 -8,317 -5,345
PBIDT 611 860 1,140 1,944 3,733 5,419 6,959 6,627 7,828
Interest -575 -1,050 -511 -974 -2,031 -2,978 -4,100 -5,321 -4,209
Depreciation -210 -247 -290 -255 -382 -477 -401 -520 -561
Taxation -25 -63 -345 -50 -228 2,876 -861 -2,012 -2,043
Exceptional Items -19 1 2,696 46 -10 -452 757 59
PAT -217 -498 2,690 711 1,082 4,840 1,145 -468 1,074

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -1,570 -1,604 -2,207 -6,956 -10,057 -15,967 -11,611 7,516 3,665
Cash Fr. Inv. -1,664 1,483 6,177 -604 -2,403 -1,768 -827 7,469 -2,772
Cash Fr. Finan. 3,281 126 -3,865 7,544 13,570 18,650 10,752 -13,019 2,072
Net Change 46 4 106 -16 1,111 916 -1,686 1,966 2,964
Cash & Cash Eqvt 269 325 447 227 1,364 2,301 623 2,612 5,582

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 46.10 46.10 46.06 46.06 46.06 46.06 46.06 46.06 43.52
Public 53.90 53.90 53.94 53.94 53.94 53.95 53.94 53.94 56.48
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Fri, 30 Jul 2021
Board Meeting Intimation for Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
PIRAMAL ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015

Technical Scans View Details

Tue, 03 Aug 2021
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone
S Close Above Last Week High
S Close Above Last Month High
CCI Overbought Zone CCI Overbought Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 190,711.14 794.85 +2.6%
Divi's Laboratories Ltd. 132,945.34 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,541.95 4,721.20 +0.4%
Cipla Ltd. 74,795.92 927.25 +0.6%
Cadila Healthcare Ltd. 60,600.44 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,835.96 4,076.05 +0.7%
Aurobindo Pharma Ltd. 53,742.29 917.20 -0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.77 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 67.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.21 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 31.10 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.40 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 391.30 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 917.20 -0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.98 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.80 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 917.20 -0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 917.20 -0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 917.20 -0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 917.20 -0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 19,159.59 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 917.20 -0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 2,401.30 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 917.20 -0.1%